Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986442 + nivolumab + carboplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986442 + nivolumab + carboplatin + pemetrexed is an investigational combination therapy for the treatment of certain solid tumors, including non-small cell lung cancer (NSCLC). **BMS-986442** is a bispecific monoclonal antibody targeting both TIGIT and CD96, designed to enhance immune response against tumors through dual inhibition in the CD226 pathway. It features an Fc-enhanced region to improve Fcγ receptor interactions, thereby further priming T cells and activating antigen-presenting cells. **Nivolumab** is a monoclonal antibody that inhibits PD-1, a checkpoint protein on immune cells, enabling the immune system to better attack cancer cells. **Carboplatin** and **pemetrexed** are chemotherapeutic agents used for cytotoxic killing of tumor cells. This combination aims to potentiate antitumor immunity and direct cytotoxic action. The lead developer is Bristol Myers Squibb, following an in-licensing from Agenus (the original developer of AGEN1777).
- Other names
- nivolumabcarboplatinpemetrexed
02
Targets
CD96 (T-cell surface protein tactile)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)GART (GAR transformylase)DHFR (Dihydrofolate reductase)TIGIT (T cell immunoreceptor with Ig and ITIM domains)DNA
Beyond the preview
Go deeper on BMS-986442 + nivolumab + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986442 + nivolumab + carboplatin + pemetrexed.